Response to treatment with TNFα inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF(+) T lymphocytes

Response to treatment with TNFα inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF(+) T lymphocytes

Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA) refractory to other treatment options. However, many patients either do not respond or relapse after initially responding to these agents. This study was carried out to identify biomarkers that can d...

Full description

Bibliographic Details
Main Authors:	Bystrom, J, Clanchy, F, Taher, T, Al-Bogami, M, Muhammad, H, Alzabin, S, Mangat, P, Jawad, A, Williams, R, Mageed, R
Format:	Journal article
Language:	English
Published:	Springer Verlag 2017

Similar Items

TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20
by: Al-Bogami, M, et al.
Published: (2020)

Unique trancriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis
by: Al-Mossawi, M, et al.
Published: (2017)

TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases
by: Bystrom, J, et al.
Published: (2016)

Characterization of the function and expression of the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor with a novel GM-CSF fusion protein
by: Rosas, M, et al.
Published: (2005)

GM-CSF primes proinflammatory monocyte responses in Ankylosing Spondylitis
by: Shi, H, et al.
Published: (2020)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
by: Lund-Palau, H, et al.
Published: (2018)

Modulation of thelper polarization by GM-CSF and the dectin-1 ligand, curdlan.
by: Loy, Yawen.
Published: (2011)

Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice.
by: Rosas, M, et al.
Published: (2007)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
by: Lund-Palau, H, et al.
Published: (2018)

ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation.
by: Pearson, C, et al.
Published: (2016)

Synergism between Curdlan and GM-CSF confers a strong inflammatory signature to Dendritic cells
by: Min, Lin, et al.
Published: (2013)

A GM-CSF eosinophil axis promotes IL-23-mediated chronic intestinal inflammation
by: Arnold, I, et al.
Published: (2014)

GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis
by: Regan-Komito, D, et al.
Published: (2020)

Anti–GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
by: Taylor, PC, et al.
Published: (2023)

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
by: Thwaites, RS, et al.
Published: (2021)

Maturation-resistant immature dendritic cells generated with low doses of GM-CSF prolong heart allograft survival in vivo
by: Lutz, M, et al.
Published: (2000)

Properties of lymph-borne (veiled) dendritic cells in culture. II. Expression of the IL-2 receptor: role of GM-CSF.
by: Macpherson, G, et al.
Published: (1989)

IL-12 and IL-18 require IFN-gamma and GM-CSF signaling, and are essential for normal bone remodeling and bone mass.
by: Sims, N, et al.
Published: (2005)

Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo.
by: Lutz, M, et al.
Published: (2000)

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway.
by: Alzabin, S, et al.
Published: (2012)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
by: Fleischmann, R, et al.
Published: (2023)

CCL11 blocks IL-4 and GM-CSF signaling in hematopoietic cells and hinders dendritic cell differentiation via suppressor of cytokine signaling expression.
by: Stevenson, N, et al.
Published: (2009)

TNFα - A pivotal role in rheumatoid arthritis?
by: Brennan, F, et al.
Published: (1992)

Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic/macrophage U937 cell line
by: Espelin, Christopher W., et al.
Published: (2012)

Harnessing the Therapeutic Potential of Th17 Cells.
by: Bystrom, J, et al.
Published: (2015)

Saturn, The GM/UAW Partnership
by: Rubinstein, Saul, et al.
Published: (2002)

STRONGLY SPECTRAL GM-SPACES
by: Edwards, C
Published: (1977)

20th anniversary of TNF inhibitors in rheumatoid arthritis
by: Taylor, P
Published: (2019)

Citrullination of autoantigens: upstream of TNFα in the pathogenesis of rheumatoid arthritis.
by: Quirke, A, et al.
Published: (2011)

Upregulation of HLA class II, but not intercellular adhesion molecule 1 (ICAM-1) by granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-3 (IL-3) in synergy with dexamethasone.
by: Sadeghi, R, et al.
Published: (1992)

ISOLATION OF YACS FOR CSF-1R AND CSF-1 AND GENE LOCALIZATION USING FISH
by: Boultwood, J, et al.
Published: (1992)

Incomplete response of inflammatory arthritis to TNF alpha blockade is associated with the Th17 pathway
by: Alzabin, S, et al.
Published: (2012)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
by: Jeyakumar, M, et al.
Published: (2003)

CSF ELECTROPHORESIS IN 1000 PATIENTS
by: Ebers, G
Published: (1980)

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial
by: Taylor, P, et al.
Published: (2019)

Synergism of glucocorticoids with granulocyte macrophage colony stimulating factor (GM-CSF) but not interferon gamma (IFN-gamma) or interleukin-4 (IL-4) on induction of HLA class II expression on human monocytes.
by: Sadeghi, R, et al.
Published: (1992)

Gm-enhanced differential colpitts VCO
by: Xiao, Xuefei
Published: (2013)

TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action
by: Elliott, M, et al.
Published: (1995)

ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
by: Feldmann, M, et al.
Published: (2011)

CSF electrophoresis in one thousand patients.
by: Ebers, G, et al.
Published: (1980)